BackFusion Pharmaceuticals Overview

Fusion Pharmaceuticals Current Assets

Track Fusion Pharmaceuticals's current assets ($220M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$220.92M
0.13% YoYΔ $293000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Fusion Pharmaceuticals Current Assets History

Loading

Fusion Pharmaceuticals vs. peers: Current Assets Comparison

Loading

Fusion Pharmaceuticals Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Fusion Pharmaceuticals (FUSN) FAQ

The latest current assets for FUSN is $220M as of March 2024. That compares with $220M in the prior-year period — up 0.1% year over year. Investors often review this figure alongside Fusion Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, FUSN's current assets moved from $220M to $220M — a 0.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fusion Pharmaceuticals's operating scale or balance-sheet position.

A current assets figure of $220M for FUSN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting FUSN's current assets ($220M), review year-over-year change from $220M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Fusion Pharmaceuticals's current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.